Graft Polymer (UK) (LSE:GPL) FCF Margin % : -97.98% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Graft Polymer (UK) FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Graft Polymer (UK)'s Free Cash Flow for the six months ended in Dec. 2023 was £-0.34 Mil. Graft Polymer (UK)'s Revenue for the six months ended in Dec. 2023 was £0.35 Mil. Therefore, Graft Polymer (UK)'s FCF Margin % for the quarter that ended in Dec. 2023 was -97.98%.

As of today, Graft Polymer (UK)'s current FCF Yield % is -214.29%.

The historical rank and industry rank for Graft Polymer (UK)'s FCF Margin % or its related term are showing as below:

LSE:GPL' s FCF Margin % Range Over the Past 10 Years
Min: -2000 Med: -250.43 Max: -34.81
Current: -250.43

During the past 6 years, the highest FCF Margin % of Graft Polymer (UK) was -34.81%. The lowest was -2000.00%. And the median was -250.43%.

LSE:GPL's FCF Margin % is ranked worse than
97.65% of 2977 companies
in the Industrial Products industry
Industry Median: 1.37 vs LSE:GPL: -250.43

Graft Polymer (UK) FCF Margin % Historical Data

The historical data trend for Graft Polymer (UK)'s FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Graft Polymer (UK) FCF Margin % Chart

Graft Polymer (UK) Annual Data

Trend

May18

May19

May20

May21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-2,000.00

-60.61

-34.81

-567.90

-250.43

Graft Polymer (UK) Semi-Annual Data
	May18	May19	May20	May21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial			-	-670.39	-407.11	-470.83	-97.98

Competitive Comparison of Graft Polymer (UK)'s FCF Margin %

For the Specialty Industrial Machinery subindustry, Graft Polymer (UK)'s FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Graft Polymer (UK)'s FCF Margin % Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Graft Polymer (UK)'s FCF Margin % distribution charts can be found below:

* The bar in red indicates where Graft Polymer (UK)'s FCF Margin % falls into.

Graft Polymer (UK) FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Graft Polymer (UK)'s FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1.47	/	0.587
	=	-250.43 %

Graft Polymer (UK)'s FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.34	/	0.347
	=	-97.98 %

Graft Polymer (UK) FCF Margin % Related Terms

Thank you for viewing the detailed overview of Graft Polymer (UK)'s FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Graft Polymer (UK) (LSE:GPL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Graft Polymer (UK) PLC (LSE:GPL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

J4I:Germany

Address

Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF

Website

https://www.graftpolymer.com

Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment.

Graft Polymer (UK) (LSE:GPL) Headlines

No Headlines